Antigenics

To see an up-to date selection of historical analyses and insights on Antigenics, visit our new, dynamically updated Company Summary report pages for Antigenics.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Antigenics are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Antigenics, or on any other Company covered by EvaluatePharma® Contact Us today.

NEWS - Selected Product News Headlines (as of 11 June 2008)
European CHMP Formally Adopts Negative Opinion on Oncophage® Preliminary Opinion Was Announced in a Press Release Issued Last Month   (Antigenics)   (Invalid Date)
Antigenics Provides Details On GlaxoSmithKline's Pivotal Malaria Vaccine Trial With QS-21 Adjuvant   (Antigenics)   (Invalid Date)
World’s Largest Malaria Vaccine Trial Now Underway in Seven African Countries   (GlaxoSmithKline)   (Invalid Date)
Data Presented on Oncophage® Cancer Vaccine in Recurrent Glioma at SNO 2009   (Antigenics)   (Invalid Date)
Antigenics facing tough decisions   (Antigenics)   (Invalid Date)
Antigenics Announces a Negative Vote From the CHMP on Oncophage® Marketing Application in Europe   (Antigenics)   (Invalid Date)
VaxGen Congratulates HIV Prime-Boost Vaccine Study Collaborators and Clarifies Commercial Rights   (VaxGen)   (Invalid Date)
Patients Begin Enrolling into Investigator-Sponsored Phase 2 Trial of Antigenics' Oncophage® Cancer Vaccine in Newly Diagnosed Glioma   (Antigenics)   (Invalid Date)
Antigenics Announces Expansion of Investigator-Sponsored Study for Glioma   (Antigenics)   (Invalid Date)
Antigenics' QS-21 Adjuvant Enters Pivotal Phase 3 Clinical Trial of GlaxoSmithKline's Malaria Vaccine   (Antigenics)   (Invalid Date)
ASCO - Cancer vaccines given boost but much work remains   (Accentia Biopharmaceuticals)   (Invalid Date)
ASCO EventAnalyzer - 2009's winners and losers   (Antigenics)   (Invalid Date)
Antigenics Presents Positive Oncophage Interim Survival Data at ASCO   (Antigenics)   (Invalid Date)
Therapeutic focus - cancer vaccines to come under scrutiny   (Accentia Biopharmaceuticals)   (Invalid Date)
FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma   (Antigenics)   (Invalid Date)
Antigenics' Oncophage Cancer Vaccine Receives European Orphan Drug Designation for Brain Cancer   (Antigenics)   (Invalid Date)

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.